Yilong Wang1, Xingquan Zhao1, Jinxi Lin1, Hao Li1, S Claiborne Johnston2, Yi Lin3, Yuesong Pan1, Liping Liu1, David Wang4, Chunxue Wang1, Xia Meng1, Jianfeng Xu5, Yongjun Wang1. 1. Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China2China National Clinical Research Center for Neurological Diseases, Beijing, China3Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China4Beijing. 2. Dell Medical School, University of Texas at Austin, Austin. 3. Department of Neurology and Institute of Neurology, First Affiliated Hospital, Fujian Medical University, Fuzhou, China. 4. Illinois Neurological Institute Stroke Network, OSF Healthcare System, University of Illinois College of Medicine, Peoria, Illinois. 5. Fudan Institute of Urology, Hushan Hospital, Fudan University, Shanghai, China9Program for Personalized Cancer Care, NorthShore University HealthSystem, Evanston, Illinois.
Abstract
IMPORTANCE: Data are limited regarding the association between CYP2C19 genetic variants and clinical outcomes of patients with minor stroke or transient ischemic attack treated withclopidogrel. OBJECTIVE: To estimate the association between CYP2C19 genetic variants and clinical outcomes of clopidogrel-treated patients with minor stroke or transient ischemic attack. DESIGN, SETTING, AND PARTICIPANTS: Three CYP2C19 major alleles (*2, *3, *17) were genotyped among 2933 Chinese patients from 73 sites who were enrolled in the Clopidogrel in High-Risk Patients with Acute Nondisabling Cerebrovascular Events (CHANCE) randomized trial conducted from January 2, 2010, to March 20, 2012. INTERVENTIONS:Patients with acute minor ischemic stroke or transient ischemic attack in the trial were randomized to treatment with clopidogrel combined with aspirin or to aspirin alone. MAIN OUTCOMES AND MEASURES: The primary efficacy outcome was new stroke. The secondary efficacy outcome was a composite of new composite vascular events (ischemic stroke, hemorrhagic stroke, myocardial infarction, or vascular death). Bleeding was the safety outcome. RESULTS: Among 2933 patients, 1948 (66.4%) were men, with a mean age of 62.4 years. Overall, 1207 patients (41.2%) were noncarriers and 1726 patients (58.8%) were carriers of loss-of-function alleles (*2, *3). After day 90 follow-up, clopidogrel-aspirin reduced the rate of new stroke in the noncarriers but not in the carriers of the loss-of-function alleles (P = .02 for interaction; events among noncarriers, 41 [6.7%] with clopidogrel-aspirin vs 74 [12.4%] with aspirin; hazard ratio [HR], 0.51 [95% CI, 0.35-0.75]; events among carriers, 80 [9.4%] with clopidogrel-aspirin vs 94 [10.8%] with aspirin; HR, 0.93 [95% CI, 0.69 to 1.26]). Similar results were observed for the secondary composite efficacy outcome (noncarriers: 41 [6.7%] with clopidogrel-aspirin vs 75 [12.5%] with aspirin; HR, 0.50 [95% CI, 0.34-0.74]; carriers: 80 [9.4%] with clopidogrel-aspirin vs 95 [10.9%] with aspirin; HR, 0.92 [95% CI, 0.68-1.24]; P = .02 for interaction). The effect of treatment assignment on bleeding did not vary significantly between the carriers and the noncarriers of the loss-of-function alleles (2.3% for carriers and 2.5% for noncarriers in the clopidogrel-aspirin group vs 1.4% for carriers and 1.7% for noncarriers in the aspirin only group; P = .78 for interaction). CONCLUSIONS AND RELEVANCE: Among patients with minor ischemic stroke or transient ischemic attack, the use of clopidogrel plus aspirin compared with aspirin alone reduced the risk of a new stroke only in the subgroup of patients who were not carriers of the CYP2C19 loss-of-function alleles. These findings support a role of CYP2C19 genotype in the efficacy of this treatment. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00979589.
RCT Entities:
IMPORTANCE: Data are limited regarding the association between CYP2C19 genetic variants and clinical outcomes of patients with minor stroke or transient ischemic attack treated with clopidogrel. OBJECTIVE: To estimate the association between CYP2C19 genetic variants and clinical outcomes of clopidogrel-treated patients with minor stroke or transient ischemic attack. DESIGN, SETTING, AND PARTICIPANTS: Three CYP2C19 major alleles (*2, *3, *17) were genotyped among 2933 Chinese patients from 73 sites who were enrolled in the Clopidogrel in High-Risk Patients with Acute Nondisabling Cerebrovascular Events (CHANCE) randomized trial conducted from January 2, 2010, to March 20, 2012. INTERVENTIONS:Patients with acute minor ischemic stroke or transient ischemic attack in the trial were randomized to treatment with clopidogrel combined with aspirin or to aspirin alone. MAIN OUTCOMES AND MEASURES: The primary efficacy outcome was new stroke. The secondary efficacy outcome was a composite of new composite vascular events (ischemic stroke, hemorrhagic stroke, myocardial infarction, or vascular death). Bleeding was the safety outcome. RESULTS: Among 2933 patients, 1948 (66.4%) were men, with a mean age of 62.4 years. Overall, 1207 patients (41.2%) were noncarriers and 1726 patients (58.8%) were carriers of loss-of-function alleles (*2, *3). After day 90 follow-up, clopidogrel-aspirin reduced the rate of new stroke in the noncarriers but not in the carriers of the loss-of-function alleles (P = .02 for interaction; events among noncarriers, 41 [6.7%] with clopidogrel-aspirin vs 74 [12.4%] with aspirin; hazard ratio [HR], 0.51 [95% CI, 0.35-0.75]; events among carriers, 80 [9.4%] with clopidogrel-aspirin vs 94 [10.8%] with aspirin; HR, 0.93 [95% CI, 0.69 to 1.26]). Similar results were observed for the secondary composite efficacy outcome (noncarriers: 41 [6.7%] with clopidogrel-aspirin vs 75 [12.5%] with aspirin; HR, 0.50 [95% CI, 0.34-0.74]; carriers: 80 [9.4%] with clopidogrel-aspirin vs 95 [10.9%] with aspirin; HR, 0.92 [95% CI, 0.68-1.24]; P = .02 for interaction). The effect of treatment assignment on bleeding did not vary significantly between the carriers and the noncarriers of the loss-of-function alleles (2.3% for carriers and 2.5% for noncarriers in the clopidogrel-aspirin group vs 1.4% for carriers and 1.7% for noncarriers in the aspirin only group; P = .78 for interaction). CONCLUSIONS AND RELEVANCE: Among patients with minor ischemic stroke or transient ischemic attack, the use of clopidogrel plus aspirin compared with aspirin alone reduced the risk of a new stroke only in the subgroup of patients who were not carriers of the CYP2C19 loss-of-function alleles. These findings support a role of CYP2C19 genotype in the efficacy of this treatment. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00979589.
Authors: Shalley N Kudalkar; Irfan Ullah; Nicole Bertoletti; Hanna K Mandl; José A Cisneros; Jagadish Beloor; Albert H Chan; Elias Quijano; W Mark Saltzman; William L Jorgensen; Priti Kumar; Karen S Anderson Journal: Antiviral Res Date: 2019-04-26 Impact factor: 5.970
Authors: Holly Tillman; S Claiborne Johnston; Mary Farrant; William Barsan; Jordan J Elm; Anthony S Kim; Anne S Lindblad; Yuko Y Palesch; J Donald Easton Journal: JAMA Neurol Date: 2019-07-01 Impact factor: 18.302
Authors: S J X Murphy; S T Lim; J A Kinsella; S Tierney; B Egan; T M Feeley; S M Murphy; R A Walsh; D R Collins; T Coughlan; D O'Neill; J A Harbison; P Madhavan; S M O'Neill; M P Colgan; D Cox; N Moran; G Hamilton; J F Meaney; D J H McCabe Journal: J Neurol Date: 2019-10-12 Impact factor: 4.849
Authors: K S Lawrence Wong; Pierre Amarenco; Gregory W Albers; Hans Denison; J Donald Easton; Scott R Evans; Peter Held; Anders Himmelmann; Scott E Kasner; Mikael Knutsson; Per Ladenvall; Kazuo Minematsu; Carlos A Molina; Yongjun Wang; S Claiborne Johnston Journal: Stroke Date: 2018-06-18 Impact factor: 7.914
Authors: S Claiborne Johnston; J Donald Easton; Mary Farrant; William Barsan; Robin A Conwit; Jordan J Elm; Anthony S Kim; Anne S Lindblad; Yuko Y Palesch Journal: N Engl J Med Date: 2018-05-16 Impact factor: 91.245